Liraglutide or Glimepiride Added to Metformin Compared for Type 2 Diabetes Glycemic Control

Type 2 diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to chronic hyperglycemia. While metformin is a cornerstone first-line therapy, many patients eventually require additional agents to maintain adequate glycemic control. Sulfonylureas like glimepiride stimulate insulin secretion but are associated with risks of hypoglycemia and weight gain. In contrast, GLP-1 receptor agonists such as liraglutide offer glucose-dependent insulin secretion, reduced glucagon, and often promote weight loss, potentially offering a more favorable profile as an add-on therapy. This trial aims to directly compare these two distinct pharmacological approaches.

This clinical trial, conducted in Asia, is designed to compare the effect on glycaemic control of two different add-on therapies to metformin. The study evaluates liraglutide or glimepiride when administered in combination with existing metformin treatment. The target population consists of subjects diagnosed with Type 2 diabetes. The primary objective is to assess the comparative efficacy and safety profiles of these two common therapeutic strategies for improving blood glucose regulation.